2022 Q1 Form 10-Q Financial Statement
#000147793222003314 Filed on May 16, 2022
Income Statement
| Concept | 2022 Q1 | 2021 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $180.0K | $181.0K |
| YoY Change | -0.55% | 7.1% |
| % of Gross Profit | ||
| Research & Development | $3.000K | $3.000K |
| YoY Change | 0.0% | 0.0% |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.000K | $1.000K |
| YoY Change | 0.0% | |
| % of Gross Profit | ||
| Operating Expenses | $3.000K | $3.000K |
| YoY Change | 0.0% | -98.26% |
| Operating Profit | -$183.0K | -$184.0K |
| YoY Change | -0.54% | |
| Interest Expense | -$464.0K | $6.000K |
| YoY Change | -7833.33% | -101.07% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$464.0K | $318.0K |
| YoY Change | -245.91% | |
| Pretax Income | -$647.0K | $134.0K |
| YoY Change | -582.84% | -118.31% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$647.0K | $134.0K |
| YoY Change | -582.84% | -118.31% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | $0.00 | $0.00 |
| Diluted Earnings Per Share | $0.00 | $0.00 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 559.3M shares | 559.3M shares |
| Diluted Shares Outstanding | 559.3M shares | 570.7M shares |
Balance Sheet
| Concept | 2022 Q1 | 2021 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $121.0K | $254.0K |
| YoY Change | -52.36% | 5.39% |
| Cash & Equivalents | $121.0K | $254.0K |
| Short-Term Investments | ||
| Other Short-Term Assets | $19.00K | $17.00K |
| YoY Change | 11.76% | -5.56% |
| Inventory | ||
| Prepaid Expenses | $19.00K | |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $440.0K | $571.0K |
| YoY Change | -22.94% | 2.15% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $3.000K | $8.000K |
| YoY Change | -62.5% | 0.0% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $2.444M | $6.199M |
| YoY Change | -60.57% | 1419.36% |
| Other Assets | $2.000K | $2.000K |
| YoY Change | 0.0% | 0.0% |
| Total Long-Term Assets | $2.449M | $6.509M |
| YoY Change | -62.38% | 539.39% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $440.0K | $571.0K |
| Total Long-Term Assets | $2.449M | $6.509M |
| Total Assets | $2.889M | $7.080M |
| YoY Change | -59.19% | 348.95% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $107.0K | $169.0K |
| YoY Change | -36.69% | -88.76% |
| Accrued Expenses | $1.201M | $935.0K |
| YoY Change | 28.45% | 40.18% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $135.0K | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $1.443M | $1.104M |
| YoY Change | 30.71% | -49.15% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $110.0K |
| YoY Change | -100.0% | 29.41% |
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $110.0K |
| YoY Change | -100.0% | 29.41% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $1.443M | $1.104M |
| Total Long-Term Liabilities | $0.00 | $110.0K |
| Total Liabilities | $1.443M | $1.214M |
| YoY Change | 18.86% | -46.19% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$69.17M | |
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $388.0K | $4.808M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $2.889M | $7.080M |
| YoY Change | -59.19% | 348.95% |
Cashflow Statement
| Concept | 2022 Q1 | 2021 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$647.0K | $134.0K |
| YoY Change | -582.84% | -118.31% |
| Depreciation, Depletion And Amortization | $1.000K | $1.000K |
| YoY Change | 0.0% | |
| Cash From Operating Activities | -$111.0K | -$96.00K |
| YoY Change | 15.63% | -4.0% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | -$3.000K |
| YoY Change | -100.0% | -25.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | |
| YoY Change | -100.0% | |
| Cash From Investing Activities | $0.00 | -$3.000K |
| YoY Change | -100.0% | -103.75% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | $0.00 | $0.00 |
| YoY Change | ||
| NET CHANGE | ||
| Cash From Operating Activities | -$111.0K | -$96.00K |
| Cash From Investing Activities | $0.00 | -$3.000K |
| Cash From Financing Activities | $0.00 | $0.00 |
| Net Change In Cash | -$111.0K | -$99.00K |
| YoY Change | 12.12% | 395.0% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$111.0K | -$96.00K |
| Capital Expenditures | $0.00 | -$3.000K |
| Free Cash Flow | -$111.0K | -$93.00K |
| YoY Change | 19.35% | -3.13% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2022Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
559281064 | shares |
| CY2022Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
559281064 | shares |
| CY2022Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.00 | |
| CY2022Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-464000 | USD |
| CY2022Q1 | us-gaap |
Notes Payable
NotesPayable
|
135000 | USD |
| CY2021Q4 | us-gaap |
Notes Payable
NotesPayable
|
130000 | USD |
| CY2022Q1 | us-gaap |
Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
|
1058000 | USD |
| CY2021Q4 | us-gaap |
Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
|
1058000 | USD |
| CY2022Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
447804 | shares |
| CY2022Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2022Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2022Q1 | us-gaap |
Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
|
0 | USD |
| CY2021Q4 | us-gaap |
Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
|
0 | USD |
| CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
559281064 | shares |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68520000 | USD |
| CY2021Q1 | us-gaap |
Revenues
Revenues
|
0 | USD |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
181000 | USD |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3000 | USD |
| CY2022Q1 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
183000 | USD |
| CY2021Q1 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
184000 | USD |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-184000 | USD |
| CY2021Q1 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
324000 | USD |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
559281064 | shares |
| CY2021Q1 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2022Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2021Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2022Q1 | mhtx |
Reclassification Of Liabilities To Equity
ReclassificationOfLiabilitiesToEquity
|
0 | USD |
| CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
318000 | USD |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-647000 | USD |
| CY2022Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
559281064 | shares |
| CY2022Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.00 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.00 | |
| CY2022Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
559281064 | shares |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
570737981 | shares |
| CY2022Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.00 | |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1035000 | USD |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-647000 | USD |
| CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
388000 | USD |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4674000 | USD |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
134000 | USD |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4808000 | USD |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-647000 | USD |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
134000 | USD |
| CY2022Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1000 | USD |
| CY2021Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1000 | USD |
| CY2022Q1 | mhtx |
Loss Gain On Fair Value Adjustment Of Investments
LossGainOnFairValueAdjustmentOfInvestments
|
457000 | USD |
| CY2021Q1 | mhtx |
Loss Gain On Fair Value Adjustment Of Investments
LossGainOnFairValueAdjustmentOfInvestments
|
-324000 | USD |
| CY2022Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
6000 | USD |
| CY2021Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
6000 | USD |
| CY2022Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
4000 | USD |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
5000 | USD |
| CY2022Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
4000 | USD |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
10000 | USD |
| CY2022Q1 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
72000 | USD |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
82000 | USD |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-111000 | USD |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-96000 | USD |
| CY2022Q1 | mhtx |
Purchase Of Fixed Assets
PurchaseOfFixedAssets
|
0 | USD |
| CY2021Q1 | mhtx |
Purchase Of Fixed Assets
PurchaseOfFixedAssets
|
-3000 | USD |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | USD |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-3000 | USD |
| CY2022Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-111000 | USD |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-99000 | USD |
| CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
232000 | USD |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
353000 | USD |
| CY2022Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
121000 | USD |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
254000 | USD |
| CY2022Q1 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2021Q1 | mhtx |
Reclassification Of Liabilities To Equity
ReclassificationOfLiabilitiesToEquity
|
0 | USD |
| CY2022Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-69167000 | USD |
| CY2022Q1 | mhtx |
Working Capital
WorkingCapital
|
-1003000 | USD |
| CY2022Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</p> | |
| CY2022Q1 | mhtx |
Cash Concentration
CashConcentration
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2022 and December 31, 2020, we had cash balances of $0 and $0 exceeding the federally insured limits.</p> | |
| CY2022Q1 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | USD |
| CY2022Q1 | us-gaap |
Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
|
0 | USD |
| CY2021 | us-gaap |
Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
|
0 | USD |
| CY2018 | mhtx |
Adjusted Asset Valuation
AdjustedAssetValuation
|
1200000 | USD |
| CY2019 | mhtx |
Sale Of Asset
SaleOfAsset
|
1200000 | USD |
| CY2021 | us-gaap |
Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
|
300000 | USD |
| CY2019Q4 | mhtx |
Remaining Amount Of Assets
RemainingAmountOfAssets
|
900000 | USD |
| CY2022Q1 | mhtx |
Common Stock Owned Share
CommonStockOwnedShare
|
52516508 | shares |
| CY2022Q1 | us-gaap |
Investments
Investments
|
2444000 | USD |
| CY2021Q4 | us-gaap |
Investments
Investments
|
2901000 | USD |
| CY2022Q1 | us-gaap |
Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
|
An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. | |
| CY2022Q1 | us-gaap |
Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
|
0 | shares |
| CY2021Q1 | us-gaap |
Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
|
0 | shares |
| CY2022Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-647000 | USD |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
134000 | USD |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
559281064 | shares |
| CY2021Q1 | mhtx |
Effect Of Dilutive Securities
EffectOfDilutiveSecurities
|
11456917 | shares |
| CY2022Q1 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
559281064 | shares |
| CY2021Q1 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
570737981 | shares |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.00 | |
| CY2022Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.00 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.00 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
26500000 | shares |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.04 | |
| CY2022Q1 | mhtx |
Weighted Average Life Outstanding Ending Balance
WeightedAverageLifeOutstandingEndingBalance
|
P6Y21D | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
26500000 | shares |
| CY2021Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
|
15000 | USD |
| CY2022Q1 | mhtx |
Begining Balance
BeginingBalance
|
2901000 | USD |
| CY2022Q1 | mhtx |
Change In The Unrealized Fair Value Of Securities
ChangeInTheUnrealizedFairValueOfSecurities
|
-457000 | USD |
| CY2022Q1 | mhtx |
Ending Balance
EndingBalance
|
2444000 | USD |
| CY2022Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
6000 | USD |
| CY2022Q1 | mhtx |
Schedule Of Debt Discount
ScheduleOfDebtDiscount
|
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Discounts on notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notes payable, net of discounts</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">135,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> | |
| CY2022Q1 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
150000 | USD |
| CY2022Q1 | mhtx |
Less Discounts On Notes Payable
LessDiscountsOnNotesPayable
|
-15000 | USD |
| CY2022Q1 | us-gaap |
Notes Payable
NotesPayable
|
135000 | USD |
| CY2022Q1 | mhtx |
Aggregate Intrinsic Value Granted
AggregateIntrinsicValueGranted
|
0 | USD |
| CY2022Q1 | mhtx |
Aggregate Intrinsic Value Exercised
AggregateIntrinsicValueExercised
|
0 | USD |
| CY2022Q1 | mhtx |
Aggregate Intrinsic Value Expired
AggregateIntrinsicValueExpired
|
0 | USD |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
26500000 | shares |
| CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.04 | |
| CY2021 | mhtx |
Weighted Average Life Outstanding Ending Balance
WeightedAverageLifeOutstandingEndingBalance
|
P5Y9M25D | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
26500000 | shares |
| CY2022Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
|
0 | USD |
| CY2022Q1 | mhtx |
Royalty Percentage On Dental Products
RoyaltyPercentageOnDentalProducts
|
0.10 | pure |
| CY2022Q1 | mhtx |
Royalty Percentage On Other Licensed Products
RoyaltyPercentageOnOtherLicensedProducts
|
0.05 | pure |
| CY2022Q1 | us-gaap |
Royalty Expense
RoyaltyExpense
|
0 | USD |
| CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1129000 | USD |
